{"product_id":"arqt-bcg-matrix","title":"(ARQT) Arcutis Biotherapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Arcutis Biotherapeutics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it easier to assess growth and capital allocation. The page already includes a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE cream 0.3% plaque psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE cream 0.3% is the FDA-approved roflumilast cream for plaque psoriasis, and it is Arcutis Biotherapeutics, Inc.’s lead commercial brand. It sits in the clearest Star slot in 2025 because it is the company’s main growth driver in dermatology, with a 0.3% strength built for chronic plaque psoriasis demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE cream 0.15% atopic dermatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE cream 0.15% is the U.S.-approved topical roflumilast for atopic dermatitis, approved by the FDA in July 2024. Atopic dermatitis affects about 31.6 million people in the U.S., so it is a large and still growing prescription market. The launch broadens Arcutis Biotherapeutics, Inc. beyond psoriasis and strengthens its Stars position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE cream 0.3% inverse psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE cream 0.3% gained a U.S. inverse psoriasis label, adding a second psoriasis use to Arcutis Biotherapeutics, Inc.'s roflumilast platform. Inverse psoriasis affects skin folds and is a niche segment, so this broadens the same branded franchise without a new molecule. That kind of label expansion can deepen reach in a high-value dermatology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZORYVE foam 0.3% seborrheic dermatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZORYVE foam 0.3% is the U.S.-approved roflumilast foam for seborrheic dermatitis, cleared by the FDA in June 2024 for patients 9 years and older. Its foam form helps treat scalp and other hair-bearing areas, so it fits a wider real-world use case than creams. That makes it a clear growth driver for Arcutis Biotherapeutics, Inc.'s brand family.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. approved, 9+ years\u003c\/li\u003e\n\u003cli\u003eFoam reaches scalp areas\u003c\/li\u003e\n\u003cli\u003eSupports brand expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZORYVE foam 0.3% plaque psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZORYVE foam 0.3% is Arcutis Biotherapeutics, Inc.’s US-approved foam for plaque psoriasis, adding a second delivery format to the same core market. In 2024, ZORYVE net product revenue reached $176.4 million, up 168% year over year, and the foam helps widen reach, support share gains, and deepen brand use.\u003c\/p\u003e\n\u003cp\u003eIt fits the Star bucket because it pairs strong market growth with rising franchise pull. Arcutis also reported 2024 total revenue of $176.9 million, with ZORYVE the main driver, and the foam can help convert more patients who prefer a leave-on format.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS-approved plaque psoriasis foam\u003c\/li\u003e\n\u003cli\u003eSecond ZORYVE delivery format\u003c\/li\u003e\n\u003cli\u003eHelps expand brand reach\u003c\/li\u003e\n\u003cli\u003eSupports share gains in core market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE: Arcutis’ breakout growth engine across three markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZORYVE is Arcutis Biotherapeutics, Inc.’s Star franchise: cream 0.3% for plaque psoriasis, cream 0.15% for atopic dermatitis, and foam 0.3% for scalp-prone seborrheic dermatitis. The brand drove 2024 net product revenue of $176.4 million, up 168% year over year, and total revenue of $176.9 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE cream 0.3%\u003c\/td\u003e\n\u003ctd\u003ePlaque psoriasis\u003c\/td\u003e\n\u003ctd\u003eLead growth driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE cream 0.15%\u003c\/td\u003e\n\u003ctd\u003eAtopic dermatitis\u003c\/td\u003e\n\u003ctd\u003eExpands addressable market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE foam 0.3%\u003c\/td\u003e\n\u003ctd\u003eSeborrheic dermatitis\u003c\/td\u003e\n\u003ctd\u003eBroadens delivery format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eArcutis Biotherapeutics’ BCG Matrix maps its dermatology products by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Arcutis Biotherapeutics, Inc. to quickly spot winners, cash drains, and next moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Arcutis Biotherapeutics, Inc. insights, boosting credibility and speeding better investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE plaque psoriasis refill base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE plaque psoriasis refills are the core cash cow for Arcutis Biotherapeutics, Inc., because plaque psoriasis is chronic and repeat prescriptions support recurring revenue. In 2024, Arcutis reported net product revenue of about $250 million, and ZORYVE was the main driver. The refill base is the most cash-generating commercial layer in the portfolio, with retention mattering more than one-time starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE inverse psoriasis maintenance use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE’s use in inverse psoriasis fits the Cash Cow box because it treats a chronic inflammatory condition, so patients often stay on therapy. Arcutis Biotherapeutics, Inc.’s once-daily, nonsteroidal roflumilast offers durable maintenance value after start-up, which supports repeat prescribing. \u003c\/p\u003e\n\u003cp\u003eThat makes it more cash-like than a pipeline asset: demand can recur month after month, with lower launch risk once access and response are established. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE seborrheic dermatitis chronic care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZORYVE seborrheic dermatitis fits Cash Cows because seborrheic dermatitis is chronic and often needs repeat treatment, so refill demand can stay steady. The U.S. FDA approved ZORYVE foam 0.3% for seborrheic dermatitis in 2023, and ongoing prescribing lowers launch spend over time. That supports durable cash flow as Arcutis Biotherapeutics, Inc. builds a repeat-use brand in a condition affecting about 3% to 5% of adults.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDermatology specialty sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. built a dedicated dermatology sales force, so the fixed selling cost can support multiple ZORYVE launches without a full rebuild each time. That scale effect helps turn rising product revenue into operating cash as the field team covers more prescribers and uses the same commercial base across indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFixed team, multiple ZORYVE launches\u003c\/li\u003e\n\u003cli\u003eLower launch cost per product\u003c\/li\u003e\n\u003cli\u003eBetter conversion of sales to cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoflumilast manufacturing platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. uses the same topical active ingredient, roflumilast, across its ZORYVE line, so one manufacturing base can support multiple formulations. That shared supply chain should lower unit costs as volume grows, which helps a Cash Cow platform keep margins improving without a matching jump in fixed spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne API across formulations\u003c\/li\u003e\n\u003cli\u003eShared plants and supply chain\u003c\/li\u003e\n\u003cli\u003eHigher volume can raise margins\u003c\/li\u003e\n\u003cli\u003eSupports a scalable cash engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZORYVE Refills Drive Arcutis’s Steady Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZORYVE refills remain Arcutis Biotherapeutics, Inc.’s main Cash Cow, because chronic plaque psoriasis, inverse psoriasis, and seborrheic dermatitis drive repeat use. Arcutis Biotherapeutics, Inc. reported about $250 million in 2024 net product revenue, led by ZORYVE. A shared roflumilast platform and one dermatology sales force help turn repeat scripts into steadier cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product revenue\u003c\/td\u003e\n\u003ctd\u003e~$250 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Cash Cow\u003c\/td\u003e\n\u003ctd\u003eZORYVE refills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eArcutis Biotherapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Arcutis Biotherapeutics, Inc. BCG Matrix report you’ll receive after purchase. The file is the same fully formatted document—no placeholders, no demo content, and no watermarks. Once purchased, it’s ready to download, edit, print, or share right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo legacy commercial brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis had no meaningful legacy commercial brands in 2025; ZORYVE generated $177.8 million in net product revenue in 2024 and remained the core asset. With no old-brand revenue base to defend, the Dogs bucket is minimal. The mix is concentrated in ZORYVE plus pipeline assets, not a long tail of low-share brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo biologic franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. has no injectable biologic franchise, so there is no mature biologic brand to tag as a \"Dog\". Its business is built on topical dermatology, led by ZORYVE (roflumilast) cream and foam, not biologics. That makes the BCG \"Dog\" bucket largely irrelevant here. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo OTC consumer line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. is a prescription dermatology company, not an OTC skin-care brand. Its portfolio centers on ZORYVE cream 0.15% and 0.3%, plus ZORYVE foam 0.3%, so it stays in higher-value Rx channels. That keeps Arcutis away from a weak, low-margin consumer tail that would dilute the BCG profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo major non-dermatology segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. is tightly focused on skin disease, with zero major non-dermatology segment in 2025 and no unrelated therapy line to drag on capital. That keeps the Dogs risk low: there is no stranded low-growth unit outside dermatology, and 100% of the business is still tied to skin-care demand and product execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100% dermatology focus in 2025.\u003c\/li\u003e\n\u003cli\u003eNo unrelated therapeutic segment.\u003c\/li\u003e\n\u003cli\u003eLower risk of stranded assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo large divested product base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. had a very compact 2025 portfolio: 1 commercial brand, ZORYVE, and no broad legacy line to prune. That means the Dogs bucket is thin, because there is no large set of aging, low-return assets in the disclosed mix. As of end-2025, no major dog asset was visible in the public portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 core commercial product\u003c\/li\u003e\n\u003cli\u003eNo large divested legacy base\u003c\/li\u003e\n\u003cli\u003eDogs exposure stays limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Has Minimal Dogs Exposure, Backed by ZORYVE Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. has almost no Dogs exposure in 2025: it had 1 core commercial product, ZORYVE, and no major legacy or unrelated brands to drag down returns. Net product revenue reached $177.8 million in 2024, and the portfolio stayed concentrated in dermatology, so weak low-share assets were not a meaningful issue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial products\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$177.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDogs exposure\u003c\/td\u003e\n\u003ctd\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARQ-252 hand eczema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARQ-252 is Arcutis Biotherapeutics, Inc.'s topical selective JAK1 inhibitor candidate for hand eczema, a chronic condition affecting about 4% to 10% of adults worldwide and often tied to work loss and poor quality of life. The market is still fragmented and no product has clear share leadership, so ARQ-252 remains a Question Mark until efficacy, safety, and commercial uptake are proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARQ-252 vitiligo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARQ-252 in vitiligo is still a Question Mark for Arcutis Biotherapeutics, Inc. The ARQ-252 platform is in development, while global vitiligo affects about 0.5% to 2% of people, so the market is real but still being shaped by new data. With several pipeline-stage rivals and limited clinical proof so far, ARQ-252 needs stronger trial results and clearer physician uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARQ-255 alopecia areata\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARQ-255 is a deeper-penetrating follow-on to ARQ-252 for alopecia areata, a disease that affects about 2% of people worldwide at some point in life. The program sits in the Question Mark box because the upside is real, but clinical and commercial proof is still limited. In a market now shaped by 3 FDA-approved systemic options, ARQ-255 still needs data to win share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext roflumilast label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoflumilast label expansion stays a Question Mark for Arcutis Biotherapeutics, Inc. because each new ZORYVE indication could add revenue without a new molecule, but approval risk remains. The upside is real: one brand can scale across more skin diseases and widen prescriber reach. Until regulators approve the next use, the revenue case is still unproven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMore labels, same molecule.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eApproval risk keeps it a Question Mark.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEach win can lift ZORYVE sales.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEx-US expansion opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. is still mostly a US story: ZORYVE is commercialized in the US only, so ex-US expansion could add a new revenue lane. That makes this a classic Question Mark in BCG terms: high upside, but no international sales base yet. Until Arcutis signs partners or launches abroad, the opportunity stays open, not proven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS-only commercial footprint\u003c\/li\u003e\n\u003cli\u003eInternational launches not yet secured\u003c\/li\u003e\n\u003cli\u003eNew markets could lift growth\u003c\/li\u003e\n\u003cli\u003eStill a Question Mark today\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis’ Question Marks Could Drive the Next Growth Wave\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. Question Marks are ARQ-252, ARQ-255, roflumilast label expansion, and ex-US ZORYVE growth: each has upside, but none has proven share yet. Hand eczema affects about 4% to 10% of adults, vitiligo 0.5% to 2% of people, and alopecia areata about 2% at some point in life.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003cth\u003eMarket cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eARQ-252\u003c\/td\u003e\n\u003ctd\u003eEarly clinical proof\u003c\/td\u003e\n\u003ctd\u003eHand eczema, 4% to 10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARQ-255\u003c\/td\u003e\n\u003ctd\u003eLimited data\u003c\/td\u003e\n\u003ctd\u003eAlopecia areata, about 2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE\u003c\/td\u003e\n\u003ctd\u003eMore labels needed\u003c\/td\u003e\n\u003ctd\u003eUS only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233959649545,"sku":"arqt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/arqt-bcg-matrix.webp?v=1785711456","url":"https:\/\/dcfanalyst.com\/products\/arqt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}